Can Medicaid patients access new sickle cell therapies?; war impacts a Kyiv chemist's work

Cutting-edge gene therapies could soon be used to treat sickle cell disease. But a potentially high price tag could hamper access. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by     STAT+: Cutting-edge gene therapies could be coming for sickle cell. Will Medicaid patients be able to access them? By Ed Silverman Alex Hogan/STAT; Adobe Cutting-edge gene therapies could soon be used to treat sickle cell disease. But a potentially high price tag could hamper access. Read More He was creating the building blocks for drug developers worldwide. Then Russia started to bomb Kyiv By Isabella Cueto Courtesy Ivan Kondratov/Enamine Suddenly, reading the latest published research, figuring out what chemical building blocks his team could synthesize, mattered little. Read More STAT+: What to know about Amylyx's ALS drug and a highly anticipated advisory panel meeting By Adam Feuerstein Adobe The Amylyx treatment isn’t likely to generate the same acrimony as Aduhelm, but it could similarly force the FDA to bend its standards. Read More Sponsor content by Harmony Biosciences Spotlight on Rare Disease: Why a patient-centric approach is vital Approximately 95 percent of the known rare diseases have no treatment. Learn more about Harmony's approach — integrating empathy with innovation to tackle rare diseases and infuse people's lives with hope, dignity, and confidence. STAT+: Armed with heaps of cash and a veteran team, an upstart looks to disrupt DNA sequencing By Jonathan Wosen Adobe The San Diego biotech announced the commercial launch of its new DNA sequencer — and with it, plans to rival industry behemoth Illumina. Read More STAT+: Combination treatment from Nektar and Bristol Myers Squibb fails to benefit patients with melanoma, study shows By Adam Feuerstein Nektar The negative trial results cast significant doubt on the future of Nektar’s lead pipeline drug called bempegaldesleukin. Read More Opinion: Commissioner Califf needs to put the F back in FDA By Bill Frist and Jerome M. Adams and Jerold Mande Matt Rourke/AP With the nation in a nutrition crisis, Commissioner Califf needs to harness the FDA's effective but underused food-related regulatory powers. Read More STAT+: Watchdog says Lilly made 'false assertions' about impact of pausing political donations after Jan. 6 attack By Ed Silverman Adobe A watchdog group argues Lilly made "false assertions" that pausing some political contributions made an impact. Read More Monday, March 14, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser